EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer

This study is testing CAR-T cell therapy targeting two proteins (EGFR and B7H3) in patients with advanced lung cancer or triple-negative breast cancer that has not responded to standard treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have advanced lung cancer or triple-negative breast cancer confirmed by biopsy - Your tumor tests positive for EGFR and/or B7H3 proteins on immunohistochemistry - Standard treatments including TKI drugs have failed - You have at least one measurable tumor lesion - Your expected survival is at least 12 weeks - Your ECOG performance status allows normal activity **You may NOT be eligible if...** - Your tumor does not express EGFR or B7H3 - Your organ function (liver, kidneys, heart) does not meet requirements - You are pregnant Talk to your doctor to see if this trial is right for you.